Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.

@article{AlBadriyeh2010PharmacoeconomicEO,
  title={Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.},
  author={Daoud Al-Badriyeh and Monica A. Slavin and Danny Liew and Karin T Thursky and Maria T Downey and Andrew Grigg and Ashish Bajel and Kay Stewart and David C. M. Kong},
  journal={The Journal of antimicrobial chemotherapy},
  year={2010},
  volume={65 5},
  pages={1052-61}
}
BACKGROUND Voriconazole and posaconazole are used prophylactically against invasive fungal infection (IFI) in patients with acute myeloid leukaemia (AML). The current study attempted to evaluate the economics of voriconazole versus posaconazole for prophylaxis in AML. METHODS A 6 year (2003-09) retrospective chart review of AML patients was performed at a major Australian tertiary hospital. Patients were followed through the induction stage of chemotherapy, estimating outcome probabilities… CONTINUE READING